Zacks Investment Research+-+-strong operational performance+-+-Pfizer forecast revenue+-+-York-based Pfizer Inc.+-+-Pfizer shares+-+-premarket trading+-+-net income+-+-Wall Street expectations+-+-biggest U.S. drugmaker+-+-Zacks stock report+-+-fellow drugmaker Allergan+-+-first-quarter net income+-+-percent+-+-pain treatment Lyrica+-+-cents+-+-lower-cost biotech drugs+-+-currency exchange rates+-+-infusion device maker+-+-legacy Hospira operations+-+-Hospira cost savings+-+-initial cost savings+-+-injectable drugmaker+-+-latest quarter+-+-injectable drugs+-+-higher sales+-+-lower tax+-+-financial forecasts+-+-business outlook+-+-prior forecast+-+-one-time items+-+-global market+-+-new class+-+-Established businesses+-+-key driver+-+-Automated Insights+-+-Ian Read+-+-chief executive+-+-earnings-per-share guidance+-+-excellent progress+-+-analysts+-+-deal+-+-range+-+-Viagra+-+-PFE+-+-remainder+-+-company+-+-record+-+-headquarters+-+-paper+-+-Ireland+-+-taxes+-+-period+-+-chairman+-+-changes+-+-purchase+-+-biosimilars+-+-Elements+-+-story+-+-http://automatedinsights.com/ap+-+-data+-+-Access+-+-board+-+-http://www.zacks.com/ap/PFE+-+-statement+-+-Standard+-+-index+-+-Tuesday+-+-Plc+-+-lift